+58.4%
SPYM vs MRNA
-27.3%
+85.7%
-24.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.5% | -2.2% | -1.4% | -3.5% |
| 7D | -8.4% | -12.7% | +4.3% | -8.0% |
| 30D | -10.7% | -20.7% | +10.0% | -10.0% |
| 3M | -9.2% | +46.3% | -55.5% | -10.8% |
| 6M | -6.4% | +305.2% | -311.6% | -16.2% |
| YTD | +2.1% | +561.2% | -559.1% | -13.8% |
| 1Y | +7.0% | +772.1% | -765.1% | -12.4% |
| 3Y | +58.0% | +147.0% | -89.0% | +40.3% |
| All | +58.4% | -27.3% | +85.7% | +46.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling